Related references
Note: Only part of the references are listed.Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Neil P. Shah et al.
LEUKEMIA & LYMPHOMA (2020)
Prospects for achieving treatment-free remission in chronic myeloid leukaemia
Giuseppe Saglio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Understanding intrinsic hematopoietic stem cell aging
Eva Mejia-Ramirez et al.
HAEMATOLOGICA (2020)
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
Shinya Kimura et al.
LANCET HAEMATOLOGY (2020)
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
Giora Sharf et al.
LEUKEMIA (2020)
Treatment-free remission in patients with chronic myeloid leukaemia
David M. Ross et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
Elisa Diral et al.
BLOOD (2020)
Another set of guidelines for chronic myeloid leukaemia
Richard E. Clark
BRITISH JOURNAL OF HAEMATOLOGY (2020)
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors
Mariella D'Adda et al.
CANCER (2019)
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
Carmen Fava et al.
HAEMATOLOGICA (2019)
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Simona Bernardi et al.
CANCER MEDICINE (2019)
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini et al.
CLINICAL CANCER RESEARCH (2019)
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2019)
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
Michele Baccarani et al.
LEUKEMIA (2019)
Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials
Katia B. Pagnano et al.
BLOOD (2019)
Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
Richard E. Clark
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
Simone Claudiani et al.
BLOOD (2019)
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update
Delphine Rea et al.
BLOOD (2019)
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)
Shin Fujisawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
Michele Baccarani et al.
BLOOD ADVANCES (2019)
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
Naoto Takahashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group
Delphine Rea et al.
CANCER (2018)
Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
Artur C. Fassoni et al.
HAEMATOLOGICA (2018)
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Naoto Takahashi et al.
HAEMATOLOGICA (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Therapy-free remission in chronic myeloid leukemia: possible mechanism
Robert Peter Gale et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
Jin Lou et al.
PATIENT PREFERENCE AND ADHERENCE (2018)
Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
Artur C. Fassoni et al.
HAEMATOLOGICA (2018)
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Naoto Takahashi et al.
HAEMATOLOGICA (2018)
Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology
Jerald P. Radich et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
Sunita Chhikara et al.
SOUTH ASIAN JOURNAL OF CANCER (2018)
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
Koji Sasaki et al.
CANCER (2018)
The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort
Naranie Shanmuganathan et al.
BLOOD (2018)
Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial
Dennis Dong Hwan Kim et al.
BLOOD (2018)
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
Takashi Kumagai et al.
CANCER SCIENCE (2018)
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M. Ilander et al.
LEUKEMIA (2017)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much
Robert Peter Gale et al.
LEUKEMIA RESEARCH (2017)
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia
Meenu Kesarwani et al.
NATURE MEDICINE (2017)
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Amy Hughes et al.
FRONTIERS IN IMMUNOLOGY (2017)
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2017)
Treatment-free remission in CML: who, how, and why?
Francois-Xavier Mahon
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Second Tyrosine Kinase Inhibitor Discontinuation Attempt in Patients With Chronic Myeloid Leukemia
Laurence Legros et al.
CANCER (2017)
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib
Fausto Castagnetti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
M. Pfirrmann et al.
LEUKEMIA (2016)
A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment
Edgar Faber et al.
LEUKEMIA & LYMPHOMA (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study
Chikashi Yoshida et al.
BLOOD (2016)
Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial
Dennis Dong Hwan Kim et al.
BLOOD (2016)
Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation
Amy Hughes et al.
BLOOD (2016)
Prognostic and predictive implications of Sokal, Euro and eutos scores in chronic myeloid leukaemia in the imatinib era-experience from tertiary oncology centre in Southern India
Lakshmaiah Chinnagiriyappa Kuntegowdanahalli et al.
ECANCERMEDICALSCIENCE (2016)
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Silvia Mori et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
The interferon-alpha revival in CML
Moshe Talpaz et al.
ANNALS OF HEMATOLOGY (2015)
Managing pregnancy in chronic myeloid leukaemia
Renuka Palani et al.
ANNALS OF HEMATOLOGY (2015)
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
V. S. Hoffmann et al.
LEUKEMIA (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
Differences among young adults, adults and elderly chronic myeloid leukemia patients
F. Castagnetti et al.
ANNALS OF ONCOLOGY (2015)
Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors
Amy Hughes et al.
BLOOD (2015)
An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians
Austin Granatowicz et al.
KOREAN JOURNAL OF FAMILY MEDICINE (2015)
First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis
Ilaria Vigano et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
David M. Ross et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase
Annie Guerin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase
Bei Hu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
Gabriel Etienne et al.
HAEMATOLOGICA (2014)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Benjamin Hanfstein et al.
HAEMATOLOGICA (2014)
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
Johan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Age-related Deterioration of Hematopoietic Stem Cells
Mi Jung Kim et al.
International Journal of Stem Cells (2014)
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
Loretta A. Williams et al.
BLOOD (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)
Noortje Thielen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M. Talpaz et al.
LEUKEMIA (2013)
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
V. S. Hoffmann et al.
LEUKEMIA (2013)
The Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950-2001
Wan-Ling Hsu et al.
RADIATION RESEARCH (2013)
Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib
Francois-Xavier Mahon et al.
BLOOD (2013)
Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI
Mette Matilda Ilander et al.
BLOOD (2013)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton et al.
BLOOD (2012)
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop Kantarjian et al.
BLOOD (2012)
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
Naoto Takahashi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Ho-Young Yhim et al.
LEUKEMIA RESEARCH (2012)
Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib - an Updated Result of the Keio STIM Study.
Eri Matsuki et al.
BLOOD (2012)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford et al.
BLOOD (2011)
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Su Chu et al.
BLOOD (2011)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal
Shreya Kanodia et al.
PLOS ONE (2010)
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
Claire M. Lucas et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A. G. Essers et al.
NATURE (2009)
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
R. Seggewiss et al.
CYTOTHERAPY (2008)
Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts
S. Polampalli et al.
GENETICS AND MOLECULAR RESEARCH (2008)
Randomized Clinical Trials and Observational Studies Guidelines for Assessing Respective Strengths and Limitations
Edward L. Hannan
JACC-CARDIOVASCULAR INTERVENTIONS (2008)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
Ingo Roeder et al.
NATURE MEDICINE (2006)
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour et al.
BLOOD (2006)
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
J Goldman et al.
LEUKEMIA & LYMPHOMA (2006)
To the editor: Discontinuation of imatinib therapy after achieving a molecular response
J Cortes et al.
BLOOD (2004)
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission
MJ Mauro et al.
LEUKEMIA RESEARCH (2004)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
The molecular biology of chronic myeloid leukemia
MWN Deininger et al.
BLOOD (2000)
The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia
RA Perego et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
